Clinical Trials Actively Recruiting
A Double-Blind, Controlled Phase 2B Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients with Chronic Motor Deficit from Ischemic Stroke
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled 21-Day Treatment Study, Including an fMRI Sub-Study to Evaluate the Effect of HT-3951 on Upper Extremity Motor Function Following Ischemic Stroke
Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the Efficacy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acetylsalicylic acid (100 mg oral q.d.) in patients with Embolic Stroke of Undetermined Source (RESPECT ESUS) [link]
Contact Tara McTigue RN, CCRC at firstname.lastname@example.org or by phone: 813.259.0826 for additional information.
Visit www.clinicaltrials.gov for more information.